Oliceridine-Propofol Dose for Gastroscope Insertion in Obese Patients
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-65
SponsorLu Yi
About this trial
The purpose of this study is to find the right dose of two medications, oliceridine and propofol, when used together for sedation in patients with obesity undergoing a painless gastroscope procedure.
Currently, standard sedation methods using other opioids can sometimes cause breathing problems, especially in patients with obesity. Oliceridine is a newer medication that may provide good pain relief with a lower risk of these side effects. However, the best dose of propofol when combined with oliceridine for this specific patient group is not yet clear.
This study will enroll patients with obesity (BMI ≥ 28 kg/m²) who are scheduled for a routine painless gastroscopy. Participants will receive the study medications during their procedure, and the medical team will carefully monitor their vital signs and sedation level. The study aims to find the most effective and safe dose combination to help guide future clinical practice.
Eligibility criteria
Qualifiers
18-65 years old, regardless of sex
BMI≥28 kg/m2
The American Society of Anesthesiologists (ASA) has a rating of II-III
Plan to undergo elective painless digestive endoscopy
Disqualifiers
Known to be allergic to drugs used in the examination process
Diagnosed respiratory diseases (asthma, bronchitis, chronic obstructive pulmonary disease, pulmonary embolism, pulmonary edema, lung cancer or upper respiratory tract infection)
Cardiovascular diseases (heart failure, unstable angina pectoris, myocardial infarction or arrhythmia) have been diagnosed
Current hepatic insufficiency (Child-Pugh grade B or above) or renal insufficiency (estimated glomerular filtration rate < 60 ml/min/1.73 m2)
Trial design
Treatments tested in this trial
- Low-Dose Oliceridine Group
- High-Dose Oliceridine Group
Treatment groups
80 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Lu Yi
Lead sponsor
Second Affiliated Hospital of Wenzhou Medical University
Sponsor institution
Source ClinicalTrials.gov